Rad Onc Resource icon

1.8 by ADF Android Development


Aug 19, 2015

About Rad Onc Resource

This application is intended for use by practitioners of radiation oncology.

Rad Onc Resource is an application intended for use by practitioners of radiation oncology. It is useful in the clinic and also for radiation treatment planning.

This version contains six features:

-Tissue Tolerance: Gives estimates of normal tissue tolerance for conventional and hypofractionated radiotherapy

-B.E.D. Calculator: Calculates biologic equivalence of different dose/fractionation schemes using the linear quadratic model

-Breast Cancer Recurrence Risk Estimator: Estimates risk of any recurrence after BCT for pN0 patients based on the EBCTCG data

-Rad Onc Wiki: Link to a very useful online evidence-based resource for radiation oncology.

-Prostate Cancer: Risk of pathologic stage based on Gleason, PSA, and Clinical Stage, as well as NCCN recommended workup

-Schonberg Index: A scientifically validated estimate of 5 year and 9 year mortality based on an 11 question survey for elderly patients.

Future versions of this application will include additional features, based on user feedback.

What's New in the Latest Version 1.8

Last updated on Aug 19, 2015

Version 1.8:

-Added social networking feature. Allows users to chat, message one another, and link to twitter
-Log in using e-mail or twitter account
-Facebook integration currently NOT available

Translation Loading...

Additional APP Information

Latest Version

Request Rad Onc Resource Update 1.8

Uploaded by

Daniel Carranza

Requires Android

Android 2.2+

Show More

Rad Onc Resource Screenshots

Comment Loading...
Languages
Searching...
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Subscribed Successfully!
You're now subscribed to APKPure.
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Success!
You're now subscribed to our newsletter.